Half-year report · HY
4361.TEDINET S100YP26
Period2025-12-01 → 2026-05-31
Filed2026-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.3bn | 2025-12-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥8.8bn | 2024-12-01 → 2025-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.3bn | 2024-12-01 → 2025-05-31 | Cons. | Net sales |
| Operating income | ¥304m | 2025-12-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥199m | 2024-12-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥285m | 2025-12-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥405m | 2024-12-01 → 2025-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥288m | 2025-12-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥9.0bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥8.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥8.8bn | at 2025-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2025-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥830m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥566m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥138m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥739m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥228m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥360m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥187m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥171.92 | 2025-12-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥245.11 | 2024-12-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.52 | 2024-12-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥288m |
| Real Estate Leasingreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-12-01 → 2026-05-31 | ¥304m |
| Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥184m |
| Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-05-31 | ¥199m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -31668000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -48114000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -8861000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -6651000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -72492000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -73041000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 186978000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -227806000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -8544000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 11779000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 528668000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 774861000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 744643000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1212523000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 1273312000 | JPY |
| Cash and cash equivalents | InterimInstant | 1987384000 | JPY |
| Employee payrolls and allowances sga | Prior1InterimDuration | 137164000 | JPY |
| Employee payrolls and allowances sga | InterimDuration | 129913000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 22673000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 3325000 | JPY |
| Provision for directors bonuses sga | Prior1InterimDuration | 4650000 | JPY |
| Provision for directors bonuses sga | InterimDuration | 7752000 | JPY |
| Provision for directors retirement benefits sga | Prior1InterimDuration | 10953000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 4143000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 127235000 | JPY |
| Research and development expenses sga | InterimDuration | 120739000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4294861000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4314059000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 4314059000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4294861000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4314059000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 4314059000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 183620000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 15327000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 198948000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 198948000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4295725000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E01006-000RealEstateLeasingReportableSegmentMember | 19283000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 4315008000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |